Department of Cardiovascular and Thoracic Surgery, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Seoul, South Korea.
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea.
J Thorac Cardiovasc Surg. 2022 Oct;164(4):e161-e171. doi: 10.1016/j.jtcvs.2020.11.163. Epub 2020 Dec 13.
We examined the safety and efficacy of del Nido cardioplegic solution compared with histidine-tryptophan-ketoglutarate cardioplegic solution in minimally invasive cardiac surgery.
Patients who underwent minimally invasive cardiac surgery using del Nido or histidine-tryptophan-ketoglutarate from 2015 to 2019 were enrolled. Various clinical outcomes were compared between the groups. Postoperative laboratory findings including the levels of electrolytes, cardiac enzymes (creatine kinase-MB and troponin I), and serial blood lactate were also measured and compared. Based on 28 baseline covariates, propensity score matching was performed to reduce selection bias.
Among 766 patients, del Nido and histidine-tryptophan-ketoglutarate were used in 330 patients (43.1%) and 436 patients (56.9%), respectively. There were no significant intergroup differences in postoperative clinical outcomes and early adverse outcomes among 228 pairs of propensity score-matched patients. Immediate postoperative sodium levels were within the normal range in both groups without a significant difference (P = .50). However, peak creatine kinase-MB (median, 31.9 vs 37.7 ng/mL, P = .026) and troponin I (6.9 vs 9.1 ng/mL, P = .014) levels were significantly lower in the del Nido group. Linear regression analysis revealed a significant association between the peak cardiac enzyme levels and the cardiac ischemic time depending on the cardioplegia type, with lower cardiac isoenzymes for del Nido over histidine-tryptophan-ketoglutarate (P < .001) until the crossover point at the cardiac ischemic time over 100 minutes.
In comparison with histidine-tryptophan-ketoglutarate solution, del Nido solution seems to have acceptable safety and efficacy with good myocardial protection in minimally invasive cardiac surgery. Further studies focusing on complex surgeries requiring longer cardiac ischemic time are needed.
研究微创心脏手术中使用 Del Nido 心脏停搏液与使用组氨酸-色氨酸-酮戊二酸心脏停搏液的安全性和有效性。
纳入 2015 年至 2019 年期间使用 Del Nido 或组氨酸-色氨酸-酮戊二酸心脏停搏液行微创心脏手术的患者。比较两组患者的各项临床结局。同时还测量和比较了术后实验室检查结果,包括电解质、心肌酶(肌酸激酶-MB 和肌钙蛋白 I)和连续血乳酸水平。基于 28 项基线协变量,进行倾向评分匹配以减少选择偏倚。
在 766 例患者中,分别有 330 例(43.1%)和 436 例(56.9%)患者使用 Del Nido 心脏停搏液和组氨酸-色氨酸-酮戊二酸心脏停搏液。在 228 对匹配后的患者中,两组间术后临床结局和早期不良结局无显著差异。两组患者术后即刻的血清钠水平均在正常范围内,差异无统计学意义(P=0.50)。然而,Del Nido 组的肌酸激酶-MB 峰浓度(中位数 31.9 vs. 37.7ng/mL,P=0.026)和肌钙蛋白 I 峰浓度(6.9 vs. 9.1ng/mL,P=0.014)均显著更低。线性回归分析显示,根据心脏停搏液类型,心肌酶峰浓度与心脏缺血时间之间存在显著关联,Del Nido 组的心肌同工酶低于组氨酸-色氨酸-酮戊二酸心脏停搏液组(P<0.001),直至心脏缺血时间超过 100 分钟时出现交叉点。
与组氨酸-色氨酸-酮戊二酸溶液相比,Del Nido 溶液在微创心脏手术中具有良好的安全性和有效性,可提供良好的心肌保护作用。需要进一步研究关注需要更长心脏缺血时间的复杂手术。